Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aims: Pre-diabetes is a common condition that affects about 16.4% of Australian adults. Hyperglycaemia is a strong risk factor for the development of stroke. Metformin XR is an approved medication to treat type 2 diabetes in Australia but not pre-diabetes. Additionally, whether it is tolerated following a stroke is unclear. In this pilot study, we aimed to assess the feasibility of Metformin XR in people with stroke and pre-diabetes.
Methods: In this PROBE design trial, people who had recent stroke (within 3 months) with pre-diabetes were randomized to either the active arm (n = 13) receiving usual care plus Metformin XR (500 mg daily increased to a total daily dose of 1500 mg) or the control group receiving only usual care (n = 13). At baseline & after four months of intervention, clinical and biomedical characteristics, cardiovascular risk factors and medication data were recorded. At one month and 2.5 months into the study, compliance rateandside effects were determined.
Results: This trial showed that it is feasible to recruit, retain and monitor participants. However, the compliance rate was low. Adherence to metformin XR was 52% (IQR:42% to 61%) based on the remaining tablets in the container after 4 months of intervention. None of the reported side effects were deemed to be related to the study treatment and no significant differences were observed between the metformin XR and the control group.
Conclusion: Treatment with Metformin XR in participants admitted with stroke and with pre-diabetes is feasible and safe. Strategies are needed to improve adherence in future trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jocn.2021.01.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adjuvant potential of metformin with standard anti-seizure medications in persons with active epilepsy: a randomised controlled trial.
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Dept. of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
The purpose of this study was to investigate the efficacy and safety of add-on metformin treatment in persons with active epilepsy (a-PWE). This is a single-centric, double-blind, placebo-controlled trial randomised a-PWE (1:1) to receive either metformin (extended-release 500 mg) or matching placebo for 6 months along with background antiseizure medications. Primary outcome was percentage change in seizure frequency/month, and secondary outcomes were 50% responder rate, serum mTOR expression, and serum total antioxidant capacity (TAC), body composition analysis, quality of life (QOL), and safety assessment.
View Article and Find Full Text PDFPrevalence and Associated Factors of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study.
Cureus
August 2025
Department of Family Medicine, Akram and Rasool Hospital, Sarai Alamgir, PAK.
Background: Patients with type 2 diabetes mellitus (T2DM) often experience hypoglycemia, an underappreciated consequence that has a major negative influence on treatment compliance and quality of life.
Objective: This study aimed to determine the prevalence and associated factors of hypoglycemia among patients with T2DM, with a focus on treatment types, comorbidities, and glycemic control. By providing population-specific data, the study intends to inform clinical decision-making and contribute to safer, more personalized diabetes management strategies.
Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.
Diabetes Obes Metab
September 2025
Department of Endocrinology, Peking University People's Hospital, Beijing, People's Republic of China.
Aim: To evaluate the long-term efficacy and safety data at 104 weeks in tirzepatide-treated participants with type 2 diabetes who had inadequate glycaemic control on metformin and/or sulfonylurea.
Materials And Methods: This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial. Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
Predictors of health care utilization in patients with post-acute sequelae of COVID-19 (PASC).
PLoS One
September 2025
The Permanente Medical Group, Pleasanton, California, United States of America.
Background: Research on Post-acute sequelae of COVID (PASC) has focused on the prevalence of symptoms, leaving gaps in our understanding of predictors of health care seeking.
Objective: To identify clinical and sociodemographic characteristics associated with PASC care seeking.
Methods: Retrospective cohort study of adult patients with COVID-19 diagnosis between January 1, 2021 and June 30, 2022 in a community-based comprehensive health care delivery system at 21 hospitals and medical clinics in Northern California.
Cohort profile: The Multiethnic Lifestyle, Obesity and Diabetes Registry in Malaysia (MeLODY) retrospective cohort in a middle-income country in Southeast Asia.
PLoS One
September 2025
Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
There is a lack of longitudinal data on type 2 diabetes (T2D) in low- and middle-income countries. We leveraged the electronic health records (EHR) system of a publicly funded academic institution to establish a retrospective cohort with longitudinal data to facilitate benchmarking, surveillance, and resource planning of a multi-ethnic T2D population in Malaysia. This cohort included 15,702 adults aged ≥ 18 years with T2D who received outpatient care (January 2002-December 2020) from Universiti Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia.
View Article and Find Full Text PDF